Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2021
Historique:
received: 07 12 2020
accepted: 11 02 2021
pubmed: 6 5 2021
medline: 29 10 2021
entrez: 5 5 2021
Statut: ppublish

Résumé

Previous studies reported an association of renal impairment with stroke, but there are uncertainties underpinning this association. We explored if the association is explained by shared risk factors or is independent and whether there are regional or stroke subtype variations. INTERSTROKE is a case-control study and the largest international study of risk factors for first acute stroke, completed in 27 countries. We included individuals with available serum creatinine values and calculated estimated glomerular filtration rate (eGFR). Renal impairment was defined as eGFR <60 mL/min/1.73 m2. Multivariable conditional logistic regression was used to determine the association of renal function with stroke. Of 21,127 participants, 41.0% were female, the mean age was 62.3 ± 13.4 years, and the mean eGFR was 79.9 ± 23.5 mL/min/1.73 m2. The prevalence of renal impairment was higher in cases (22.9% vs. 17.7%, p < 0.001) and differed by region (p < 0.001). After adjustment, lower eGFR was associated with increased odds of stroke. Renal impairment was associated with increased odds of all stroke (OR 1.35; 95% CI: 1.24-1.47), with higher odds for intracerebral hemorrhage (OR 1.60; 95% CI: 1.35-1.89) than ischemic stroke (OR 1.29; 95% CI: 1.17-1.42) (pinteraction 0.12). The largest magnitudes of association were seen in younger participants and those living in Africa, South Asia, or South America (pinteraction < 0.001 for all stroke). Renal impairment was also associated with poorer clinical outcome (RRR 2.97; 95% CI: 2.50-3.54 for death within 1 month). Renal impairment is an important risk factor for stroke, particularly in younger patients, and is associated with more severe stroke and worse outcomes.

Sections du résumé

BACKGROUND
Previous studies reported an association of renal impairment with stroke, but there are uncertainties underpinning this association.
AIMS
We explored if the association is explained by shared risk factors or is independent and whether there are regional or stroke subtype variations.
METHODS
INTERSTROKE is a case-control study and the largest international study of risk factors for first acute stroke, completed in 27 countries. We included individuals with available serum creatinine values and calculated estimated glomerular filtration rate (eGFR). Renal impairment was defined as eGFR <60 mL/min/1.73 m2. Multivariable conditional logistic regression was used to determine the association of renal function with stroke.
RESULTS
Of 21,127 participants, 41.0% were female, the mean age was 62.3 ± 13.4 years, and the mean eGFR was 79.9 ± 23.5 mL/min/1.73 m2. The prevalence of renal impairment was higher in cases (22.9% vs. 17.7%, p < 0.001) and differed by region (p < 0.001). After adjustment, lower eGFR was associated with increased odds of stroke. Renal impairment was associated with increased odds of all stroke (OR 1.35; 95% CI: 1.24-1.47), with higher odds for intracerebral hemorrhage (OR 1.60; 95% CI: 1.35-1.89) than ischemic stroke (OR 1.29; 95% CI: 1.17-1.42) (pinteraction 0.12). The largest magnitudes of association were seen in younger participants and those living in Africa, South Asia, or South America (pinteraction < 0.001 for all stroke). Renal impairment was also associated with poorer clinical outcome (RRR 2.97; 95% CI: 2.50-3.54 for death within 1 month).
CONCLUSION
Renal impairment is an important risk factor for stroke, particularly in younger patients, and is associated with more severe stroke and worse outcomes.

Identifiants

pubmed: 33951632
pii: 000515239
doi: 10.1159/000515239
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-215

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Andrew Smyth (A)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
HRB Clinical Research Facility Galway, School of Medicine, NUI Galway, Galway, Ireland.
Department of Nephrology, Galway University Hospitals, Galway, Ireland.

Conor Judge (C)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
HRB Clinical Research Facility Galway, School of Medicine, NUI Galway, Galway, Ireland.
Department of Nephrology, Galway University Hospitals, Galway, Ireland.

Xingu Wang (X)

Beijing Hypertension League Institute, Beijing, China.

Guillaume Pare (G)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Sumathy Rangarajan (S)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Michelle Canavan (M)

HRB Clinical Research Facility Galway, School of Medicine, NUI Galway, Galway, Ireland.

Siu Lim Chin (SL)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Fawaz Al-Hussain (F)

King Saud University, Riyadh, Saudi Arabia.

Afzalhussein M Yusufali (AM)

Dubai Health Authority, Dubai Medical College, Dubai, United Arab Emirates.

Ahmed Elsayed (A)

Alzaeim Alazhari University, Khartoum North, Sudan.

Albertino Damasceno (A)

Eduardo Mondlane University, Maputo, Mozambique.

Alvaro Avezum (A)

Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil.

Anna Czlonkowska (A)

Institute of Psychiatry and Neurology, Warsaw, Poland.

Annika Rosengren (A)

Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Antonio L Dans (AL)

College of Medicine, University of Philippines, Manila, Philippines.

Aytekin Oguz (A)

Department of Internal Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.

Charles Mondo (C)

Uganda Heart Institute, Mulago Hospital, Kampala, Uganda.

Christian Weimar (C)

Department of Neurology, University Hospital, Essen, Germany.

Danuta Ryglewicz (D)

Military Institute of Aviation Medicine, Warsaw, Poland.

Denis Xavier (D)

St John's Medical College and Research Institute, Bangalore, India.

Fernando Lanas (F)

Faculty of Medicine, Universidad de La Frontera, Temuco, Chile.

German Malaga (G)

Universidad Peruana Cayetano Heredia, Lima, Peru.

Graeme J Hankey (GJ)

School of Medicine and Pharmacology, The University of Western Australia, Perth, Washington, Australia.

Helle K Iversen (HK)

Stroke Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Hongye Zhang (H)

Beijing Hypertension League Institute, Beijing, China.

Khalid Yusoff (K)

Universiti Teknologi MARA, Selayang, Selangor, Malaysia, UCSI University, Cheras, Kuala Lumpur, Malaysia.

Nana Pogosova (N)

National Medical Research Center of Cardiology, Moscow, Russian Federation.

Patricio Lopez-Jamarillo (P)

Instituto de Investigaciones FOSCAL, Escuela de Medicina, Universidad de Santander, Bucaramanga, Colombia.

Peter Langhorne (P)

Academic Section of Geriatric Medicine, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom.

Rafael Diaz (R)

Estudios Clinicos Latinoamerica, Rosario, Argentina.

Shahram Oveisgharan (S)

Rush Alzheimer Disease Research Center, Rush University Medical Center, Chicago, Illinois, USA.

Salim Yusuf (S)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Martin O'Donnell (M)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
HRB Clinical Research Facility Galway, School of Medicine, NUI Galway, Galway, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH